Skip to main content
Top
Published in: BMC Cancer 1/2015

Open Access 01-12-2015 | Study protocol

A phase II RCT and economic analysis of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy

Authors: Shabbir MH Alibhai, Daniel Santa Mina, Paul Ritvo, Catherine Sabiston, Murray Krahn, George Tomlinson, Andrew Matthew, Roanne Segal, Padraig Warde, Sara Durbano, Meagan O’Neill, Nicole Culos-Reed

Published in: BMC Cancer | Issue 1/2015

Login to get access

Abstract

Background

Androgen deprivation therapy is commonly used to treat prostate cancer, the most common visceral cancer in men. However, various side effects often worsen physical functioning and reduce well-being among men on this treatment. Based on existing evidence, both resistance and aerobic training provide benefits for this population yet adherence rates are often low. The method of exercise delivery (supervised in-center or home-based) may be important, yet few studies have compared different models. Additionally, long-term exercise adherence is critical to achieve sustained benefits but long-term adherence data and predictors of adherence are lacking. The primary aim of this phase II, non-inferiority randomized controlled trial is to determine whether three exercise training delivery models are equivalent in terms of benefits in quality of life and physical fitness in this population. Secondary aims include examination of long-term adherence and cost-effectiveness.

Design

Men diagnosed with prostate cancer, starting or continuing on androgen deprivation therapy for at least 6 months, fluent in English, and living close to one of two experienced Canadian study centers are eligible. Participants complete five assessments over one year, including a fitness assessment and self-report questionnaires. Socio-demographic and clinical data collection occur at baseline, bone mineral density testing at two time points, and blood work is performed at three time points. Participants are randomized in a 1:1:1 fashion to supervised personal training, supervised group training, or home-based smartphone- and health coach-supported training. Each participant receives a detailed exercise manual, including illustrations of exercises and safety precautions. Participants are asked to complete 4 to 5 exercise sessions per week, incorporating aerobic, resistance and flexibility training. Participant intensity levels will be monitored. The intervention duration is 6 months, with 6 months additional follow-up. Outcomes include: body composition, fitness testing, quality of life and fatigue, biological outcomes, and program adherence. Cost information will be obtained using patient diary-based self-report.

Discussion

The goals of this study are to gain a better understanding of health benefits and costs associated with commonly used yet currently not compared exercise delivery models as well as an increased understanding of adherence to exercise.

Trial registration

The trial has been registered at clinicaltrials.gov (Registration # NCT02046837), registered January 20th, 2014.
Literature
1.
go back to reference Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian Cancer Society: Canadian Cancer Statistics 2014. Toronto, 2014 Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian Cancer Society: Canadian Cancer Statistics 2014. Toronto, 2014
2.
3.
go back to reference Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103(8):1615–24.CrossRefPubMed Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103(8):1615–24.CrossRefPubMed
4.
go back to reference Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst. 2003;95(13):981–9.CrossRefPubMedPubMedCentral Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst. 2003;95(13):981–9.CrossRefPubMedPubMedCentral
5.
go back to reference Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238–44.CrossRefPubMed Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238–44.CrossRefPubMed
6.
go back to reference Alibhai SMH, Breunis H, Timilshina N, Johnston C, Tomlinson G, Tannock I, et al. Impact of androgen-deprivation therapy on physical function and quality of life in men with non-metastatic prostate cancer. J Clin Oncol. 2010;28(34):5038–45.CrossRefPubMed Alibhai SMH, Breunis H, Timilshina N, Johnston C, Tomlinson G, Tannock I, et al. Impact of androgen-deprivation therapy on physical function and quality of life in men with non-metastatic prostate cancer. J Clin Oncol. 2010;28(34):5038–45.CrossRefPubMed
7.
go back to reference Alibhai SM, Gogov S, Allibhai Z. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol. 2006;60(3):201–15.CrossRefPubMed Alibhai SM, Gogov S, Allibhai Z. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol. 2006;60(3):201–15.CrossRefPubMed
8.
go back to reference Walker LM, Tran S, Robinson JW. Luteinizing hormone–releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects. Clin Genitourin Canc. 2013;11(4):375–84.CrossRef Walker LM, Tran S, Robinson JW. Luteinizing hormone–releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects. Clin Genitourin Canc. 2013;11(4):375–84.CrossRef
9.
go back to reference Baumann FT, Zopf EM, Bloch W. Clinical exercise interventions in prostate cancer patients–a systematic review of randomized controlled trials. Support Care Cancer. 2012;20(2):221–33.CrossRefPubMed Baumann FT, Zopf EM, Bloch W. Clinical exercise interventions in prostate cancer patients–a systematic review of randomized controlled trials. Support Care Cancer. 2012;20(2):221–33.CrossRefPubMed
10.
go back to reference Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2003;21(9):1653–9.CrossRefPubMed Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2003;21(9):1653–9.CrossRefPubMed
11.
go back to reference Galvao DA, Nosaka K, Taaffe DR, Spry N, Kristjanson LJ, McGuigan MR, et al. Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc. 2006;38(12):2045–52.CrossRefPubMed Galvao DA, Nosaka K, Taaffe DR, Spry N, Kristjanson LJ, McGuigan MR, et al. Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc. 2006;38(12):2045–52.CrossRefPubMed
12.
go back to reference Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol. 2010;28(2):340–7.CrossRefPubMed Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol. 2010;28(2):340–7.CrossRefPubMed
13.
go back to reference Thorsen L, Courneya KS, Stevinson C, Fossa SD. A systematic review of physical activity in prostate cancer survivors: outcomes, prevalence, and determinants. Support Care Cancer. 2008;16(9):987–97.CrossRefPubMed Thorsen L, Courneya KS, Stevinson C, Fossa SD. A systematic review of physical activity in prostate cancer survivors: outcomes, prevalence, and determinants. Support Care Cancer. 2008;16(9):987–97.CrossRefPubMed
14.
go back to reference Santa Mina D, Ritvo P, Segal R, Culos-Reed SN, Alibhai SMH. Exercise After Prostate Cancer Diagnosis. In: Saxton JM, Daley A, editors. Exercise and Cancer Survivorship: Impact on Health Outcomes and Quality of Life. New York: Springer; 2010. p. 113–40.CrossRef Santa Mina D, Ritvo P, Segal R, Culos-Reed SN, Alibhai SMH. Exercise After Prostate Cancer Diagnosis. In: Saxton JM, Daley A, editors. Exercise and Cancer Survivorship: Impact on Health Outcomes and Quality of Life. New York: Springer; 2010. p. 113–40.CrossRef
15.
go back to reference Keogh JW, MacLeod RD. Body composition, physical fitness, functional performance, quality of life, and fatigue benefits of exercise for prostate cancer patients: a systematic review. J Pain Symptom Manage. 2012;43(1):96–110.CrossRefPubMed Keogh JW, MacLeod RD. Body composition, physical fitness, functional performance, quality of life, and fatigue benefits of exercise for prostate cancer patients: a systematic review. J Pain Symptom Manage. 2012;43(1):96–110.CrossRefPubMed
16.
go back to reference Gardner JR, Livingston PM, Fraser SF. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J Clin Oncol. 2014;32(4):335–46.CrossRefPubMed Gardner JR, Livingston PM, Fraser SF. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J Clin Oncol. 2014;32(4):335–46.CrossRefPubMed
17.
go back to reference Borst SE. Interventions for sarcopenia and muscle weakness in older people. Age Ageing. 2004;33(6):548–55.CrossRefPubMed Borst SE. Interventions for sarcopenia and muscle weakness in older people. Age Ageing. 2004;33(6):548–55.CrossRefPubMed
18.
go back to reference Santa Mina D, Ritvo P, Matthew AG, Rampersad A, Stein H, Cheung AM, et al. Group exercise versus personal training for prostate cancer patients: a pilot randomized trial. J Canc Ther. 2012;3(2):146–56.CrossRef Santa Mina D, Ritvo P, Matthew AG, Rampersad A, Stein H, Cheung AM, et al. Group exercise versus personal training for prostate cancer patients: a pilot randomized trial. J Canc Ther. 2012;3(2):146–56.CrossRef
19.
go back to reference Hansen PA, Dechet CB, Porucznik CA, LaStayo PC. Comparing eccentric resistance exercise in prostate cancer survivors on and off hormone therapy: a pilot study. Phys Rehabil Med. 2009;1(11):1019–24. Hansen PA, Dechet CB, Porucznik CA, LaStayo PC. Comparing eccentric resistance exercise in prostate cancer survivors on and off hormone therapy: a pilot study. Phys Rehabil Med. 2009;1(11):1019–24.
20.
go back to reference Bourke L, Doll H, Crank H, Daley A, Rosario D, Saxton JM. Lifestyle intervention in men with advanced prostate cancer receiving androgen suppression therapy: a feasibility study. Canc Epidemiol Biomarkers Prev. 2011;20(4):647–57.CrossRef Bourke L, Doll H, Crank H, Daley A, Rosario D, Saxton JM. Lifestyle intervention in men with advanced prostate cancer receiving androgen suppression therapy: a feasibility study. Canc Epidemiol Biomarkers Prev. 2011;20(4):647–57.CrossRef
21.
go back to reference Culos-Reed SN, Robinson JL, Lau H, O’Connor K, Keats MR. Benefits of a physical activity intervention for men with prostate cancer. J Sport Exerc Psychol. 2007;29(1):118–27.CrossRefPubMed Culos-Reed SN, Robinson JL, Lau H, O’Connor K, Keats MR. Benefits of a physical activity intervention for men with prostate cancer. J Sport Exerc Psychol. 2007;29(1):118–27.CrossRefPubMed
22.
go back to reference Culos-Reed SN, Robinson JW, Lau H, Stephenson L, Keats M, Norris S, et al. Physical activity for Men receiving androgen deprivation therapy for prostate cancer: benefits from a 16-week intervention. Support Care Cancer. 2010;18(5):591–9.CrossRefPubMed Culos-Reed SN, Robinson JW, Lau H, Stephenson L, Keats M, Norris S, et al. Physical activity for Men receiving androgen deprivation therapy for prostate cancer: benefits from a 16-week intervention. Support Care Cancer. 2010;18(5):591–9.CrossRefPubMed
23.
go back to reference Windsor PM, Nicol KF, Potter J. A randomized, controlled trial of aerobic exercise for treatment-related fatigue in men receiving radical external beam radiotherapy for localized prostate carcinoma. Cancer. 2004;101(3):550–7.CrossRefPubMed Windsor PM, Nicol KF, Potter J. A randomized, controlled trial of aerobic exercise for treatment-related fatigue in men receiving radical external beam radiotherapy for localized prostate carcinoma. Cancer. 2004;101(3):550–7.CrossRefPubMed
24.
go back to reference Canadian Society of Exercise Physiology. Physical Activity Readiness Questionnaire. Ottawa: Canadian Society of Exercise Physiology; 2002. Canadian Society of Exercise Physiology. Physical Activity Readiness Questionnaire. Ottawa: Canadian Society of Exercise Physiology; 2002.
25.
go back to reference Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU. Acute versus chronic exposure to androgen suppression for prostate cancer: impact on the exercise response. J Urol. 2011;186(4):1291–7.CrossRefPubMed Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU. Acute versus chronic exposure to androgen suppression for prostate cancer: impact on the exercise response. J Urol. 2011;186(4):1291–7.CrossRefPubMed
26.
go back to reference Canadian Society of Exercise Physiology. Physical Activity Training for Health. Ottawa: Health Canada; 2013. Canadian Society of Exercise Physiology. Physical Activity Training for Health. Ottawa: Health Canada; 2013.
27.
go back to reference Canadian Society of Exercise Physiology. The Canadian Physical Activity, Fitness & Lifestyle Approach. 3rd ed. Ottawa: Health Canada; 2010. Canadian Society of Exercise Physiology. The Canadian Physical Activity, Fitness & Lifestyle Approach. 3rd ed. Ottawa: Health Canada; 2010.
28.
go back to reference American College of Sports Medicine. ACSM’s Guidelines for Exercise Testing and Prescription. New York: Lippincott Williams and Winkins; 2005. American College of Sports Medicine. ACSM’s Guidelines for Exercise Testing and Prescription. New York: Lippincott Williams and Winkins; 2005.
29.
go back to reference Strassmann A, Steurer-Stey C, Lana KD, Zoller M, Turk AJ, Suter P, et al. Population-based reference values for the 1-min sit-to-stand test. Int J Publ Health. 2013;58(6):949–53.CrossRef Strassmann A, Steurer-Stey C, Lana KD, Zoller M, Turk AJ, Suter P, et al. Population-based reference values for the 1-min sit-to-stand test. Int J Publ Health. 2013;58(6):949–53.CrossRef
30.
go back to reference Bohannon RW. Sit-to-stand test for measuring performance of lower extremity muscles. Percept Mot Skills. 1995;80(1):163–6.CrossRefPubMed Bohannon RW. Sit-to-stand test for measuring performance of lower extremity muscles. Percept Mot Skills. 1995;80(1):163–6.CrossRefPubMed
31.
go back to reference Mathiowetz V, Kashman N, Volland G, Weber K, Dowe M, Rogers S. Grip and pinch strength: normative data for adults. Arch Phys Med Rehabil. 1985;66(2):69–74.PubMed Mathiowetz V, Kashman N, Volland G, Weber K, Dowe M, Rogers S. Grip and pinch strength: normative data for adults. Arch Phys Med Rehabil. 1985;66(2):69–74.PubMed
32.
go back to reference Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–9.PubMed Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–9.PubMed
33.
go back to reference Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology. 1997;50(6):920–8.CrossRefPubMed Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology. 1997;50(6):920–8.CrossRefPubMed
34.
go back to reference Cella D. The functional assessment of cancer therapy-anemia (FACT-an) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997;34(3 Suppl 2):13–9.PubMed Cella D. The functional assessment of cancer therapy-anemia (FACT-an) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997;34(3 Suppl 2):13–9.PubMed
35.
go back to reference Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, Cheung AM, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol. 2009;27(21):3452–8.CrossRefPubMed Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, Cheung AM, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol. 2009;27(21):3452–8.CrossRefPubMed
36.
go back to reference Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2009;181(5):1998–2006. discussion 2007–1998.CrossRefPubMedPubMedCentral Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2009;181(5):1998–2006. discussion 2007–1998.CrossRefPubMedPubMedCentral
37.
go back to reference Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.CrossRefPubMed Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.CrossRefPubMed
38.
go back to reference Kraemer WJ, Ratamess NA. Hormonal responses and adaptations to resistance exercise and training. Sports Med. 2005;35(4):339–61.CrossRefPubMed Kraemer WJ, Ratamess NA. Hormonal responses and adaptations to resistance exercise and training. Sports Med. 2005;35(4):339–61.CrossRefPubMed
39.
go back to reference Segal RJ, Reid RD, Courneya KS, Sigal RJ, Kenny GP, Prud’Homme DG, et al. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol. 2009;27(3):344–51.CrossRefPubMed Segal RJ, Reid RD, Courneya KS, Sigal RJ, Kenny GP, Prud’Homme DG, et al. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol. 2009;27(3):344–51.CrossRefPubMed
40.
go back to reference Prince SA, Adamo KB, Hamel ME, Hardt J, Connor Gorber S, Tremblay M. A comparison of direct versus self-report measures for assessing physical activity in adults: a systematic review. Int J Behav Nutr Phys Act. 2008;5:56.CrossRefPubMedPubMedCentral Prince SA, Adamo KB, Hamel ME, Hardt J, Connor Gorber S, Tremblay M. A comparison of direct versus self-report measures for assessing physical activity in adults: a systematic review. Int J Behav Nutr Phys Act. 2008;5:56.CrossRefPubMedPubMedCentral
41.
go back to reference Canadian Society of Exercise Physiology. Canadian Physical Activity Guidelines. Ottawa: Health Canada; 2011. Canadian Society of Exercise Physiology. Canadian Physical Activity Guidelines. Ottawa: Health Canada; 2011.
42.
go back to reference Freedson PS, Melanson E, Sirard J. Calibration of the Computer Science and Applications, Inc. accelerometer. Med Sci Sports Exerc. 1998;30(5):777–81.CrossRefPubMed Freedson PS, Melanson E, Sirard J. Calibration of the Computer Science and Applications, Inc. accelerometer. Med Sci Sports Exerc. 1998;30(5):777–81.CrossRefPubMed
43.
go back to reference Tudor-Locke C, Craig CL, Aoyagi Y, Bell RC, Croteau KA, De Bourdeaudhuij I, et al. How many steps/day are enough? For older adults and special populations. Int J Behav Nutr Phys Act. 2011;8:80.CrossRefPubMedPubMedCentral Tudor-Locke C, Craig CL, Aoyagi Y, Bell RC, Croteau KA, De Bourdeaudhuij I, et al. How many steps/day are enough? For older adults and special populations. Int J Behav Nutr Phys Act. 2011;8:80.CrossRefPubMedPubMedCentral
44.
go back to reference Bronfenbrenner U. Environments in developmental perspective: Theoretical and operational models. In: Friedmand SL, Wachs TD, editors. Measuring Environment Across the Life Span. Washington, D.C: American Psychological Association; 1999. p. 3–28.CrossRef Bronfenbrenner U. Environments in developmental perspective: Theoretical and operational models. In: Friedmand SL, Wachs TD, editors. Measuring Environment Across the Life Span. Washington, D.C: American Psychological Association; 1999. p. 3–28.CrossRef
45.
go back to reference Cerin E, Saelens BE, Sallis JF, Frank LD. Neighborhood Environment Walkability Scale: validity and development of a short form. Med Sci Sports Exerc. 2006;38(9):1682–91.CrossRefPubMed Cerin E, Saelens BE, Sallis JF, Frank LD. Neighborhood Environment Walkability Scale: validity and development of a short form. Med Sci Sports Exerc. 2006;38(9):1682–91.CrossRefPubMed
46.
go back to reference Williams GC, Grow VM, Freedman ZR, Ryan RM, Deci EL. Motivational predictors of weight loss and weight-loss maintenance. J Pers Soc Psychol. 1996;70(1):115–26.CrossRefPubMed Williams GC, Grow VM, Freedman ZR, Ryan RM, Deci EL. Motivational predictors of weight loss and weight-loss maintenance. J Pers Soc Psychol. 1996;70(1):115–26.CrossRefPubMed
47.
go back to reference Wilson PM, Garcia Bengoechea E. The relatedness to others in physical activity scale: evidence for structural and criterion validity. J Appl Biobehav Res. 2010;15(2):61–87.CrossRef Wilson PM, Garcia Bengoechea E. The relatedness to others in physical activity scale: evidence for structural and criterion validity. J Appl Biobehav Res. 2010;15(2):61–87.CrossRef
48.
go back to reference Markland DA, Tobin V. A modification to the behavioural regulation in exercise questionnaire to include an assessment of amotivation. J Sport Exerc Psychol. 2004;26:191–6.CrossRef Markland DA, Tobin V. A modification to the behavioural regulation in exercise questionnaire to include an assessment of amotivation. J Sport Exerc Psychol. 2004;26:191–6.CrossRef
49.
go back to reference Brunet J, Sabiston CM. Exploring motivation for physical activity across the adult lifespan. Psychol Sport Exerc. 2011;12:99–105.CrossRef Brunet J, Sabiston CM. Exploring motivation for physical activity across the adult lifespan. Psychol Sport Exerc. 2011;12:99–105.CrossRef
50.
go back to reference Courneya KS, Friedenreich CM. Utility of the theory of planned behavior for understanding exercise during breast cancer treatment. Psychooncology. 1999;8(2):112–22.CrossRefPubMed Courneya KS, Friedenreich CM. Utility of the theory of planned behavior for understanding exercise during breast cancer treatment. Psychooncology. 1999;8(2):112–22.CrossRefPubMed
51.
go back to reference Courneya KS, Vallance JK, Culos-Reed SN, McNeely ML, Bell GJ, Mackey JR, et al. The Alberta moving beyond breast cancer (AMBER) cohort study: a prospective study of physical activity and health-related fitness in breast cancer survivors. BMC Cancer. 2012;12:525.CrossRefPubMedPubMedCentral Courneya KS, Vallance JK, Culos-Reed SN, McNeely ML, Bell GJ, Mackey JR, et al. The Alberta moving beyond breast cancer (AMBER) cohort study: a prospective study of physical activity and health-related fitness in breast cancer survivors. BMC Cancer. 2012;12:525.CrossRefPubMedPubMedCentral
52.
53.
go back to reference Heyward VH. Advanced Fitness Assessment and Exercise Prescription. 5th ed. Windsor: Human Kinetics Publishers; 2010. Heyward VH. Advanced Fitness Assessment and Exercise Prescription. 5th ed. Windsor: Human Kinetics Publishers; 2010.
55.
go back to reference Roset M, Badia X, Mayo NE. Sample size calculations in studies using the EuroQol 5D. Qual Life Res. 1999;8(6):539–49.CrossRefPubMed Roset M, Badia X, Mayo NE. Sample size calculations in studies using the EuroQol 5D. Qual Life Res. 1999;8(6):539–49.CrossRefPubMed
56.
go back to reference Krahn M, Bremner KE, Tomlinson G, Ritvo P, Irvine J, Naglie G. Responsiveness of disease-specific and generic utility instruments in prostate cancer patients. Qual Life Res. 2007;16(3):509–22.CrossRefPubMed Krahn M, Bremner KE, Tomlinson G, Ritvo P, Irvine J, Naglie G. Responsiveness of disease-specific and generic utility instruments in prostate cancer patients. Qual Life Res. 2007;16(3):509–22.CrossRefPubMed
57.
go back to reference Krahn M, Ritvo P, Irvine J, Tomlinson G, Bremner KE, Bezjak A, et al. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care. 2003;41(1):153–64.CrossRefPubMed Krahn M, Ritvo P, Irvine J, Tomlinson G, Bremner KE, Bezjak A, et al. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care. 2003;41(1):153–64.CrossRefPubMed
58.
59.
go back to reference Hertzog MA. Considerations in determining sample size for pilot studies. Res Nurs Health. 2008;31(2):180–91.CrossRefPubMed Hertzog MA. Considerations in determining sample size for pilot studies. Res Nurs Health. 2008;31(2):180–91.CrossRefPubMed
60.
go back to reference Sim J, Lewis M. The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency. J Clin Epidemiol. 2012;65(3):301–8.CrossRefPubMed Sim J, Lewis M. The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency. J Clin Epidemiol. 2012;65(3):301–8.CrossRefPubMed
61.
go back to reference Demark-Wahnefried W, Clipp EC, Lipkus IM, Lobach D, Snyder DC, Sloane R, et al. Main outcomes of the FRESH START trial: a sequentially tailored, diet and exercise mailed print intervention among breast and prostate cancer survivors. J Clin Oncol. 2007;25(19):2709–18.CrossRefPubMed Demark-Wahnefried W, Clipp EC, Lipkus IM, Lobach D, Snyder DC, Sloane R, et al. Main outcomes of the FRESH START trial: a sequentially tailored, diet and exercise mailed print intervention among breast and prostate cancer survivors. J Clin Oncol. 2007;25(19):2709–18.CrossRefPubMed
62.
go back to reference Richman EL, Kenfield SA, Stampfer MJ, Paciorek A, Carroll PR, Chan JM. Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavor. Cancer Res. 2011;71(11):3889–95.CrossRefPubMedPubMedCentral Richman EL, Kenfield SA, Stampfer MJ, Paciorek A, Carroll PR, Chan JM. Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavor. Cancer Res. 2011;71(11):3889–95.CrossRefPubMedPubMedCentral
Metadata
Title
A phase II RCT and economic analysis of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy
Authors
Shabbir MH Alibhai
Daniel Santa Mina
Paul Ritvo
Catherine Sabiston
Murray Krahn
George Tomlinson
Andrew Matthew
Roanne Segal
Padraig Warde
Sara Durbano
Meagan O’Neill
Nicole Culos-Reed
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-015-1316-8

Other articles of this Issue 1/2015

BMC Cancer 1/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine